There is evidence that the IGF system has an important pathophysiological role across the spectrum of obesity, insulin resistance and type 2 diabetes mellitus, and therefore represents a potential therapeutic target. This evidence concerns the gene IGF1 and obesity due to melanocortin 4 receptor deficiency.